Biohaven Expands Oncology Pipeline with Regeneron Collaboration

The upcoming presentation, scheduled for October 23, 2026, will detail findings from an ongoing Phase 1 dose-escalation study. Preliminary results indicate that BHV-1530 demonstrates antitumor activity in both FGFR3-altered and wild-type overexpressing tumors. Notably, the therapy has been well-tolerated in heavily pretreated patients, avoiding the dose-limiting toxicities often associated with traditional FGFR tyrosine kinase inhibitors, such as stomatitis and retinopathy.

By targeting FGFR3 regardless of genomic alteration status, the drug potentially addresses a significantly larger patient population than current standards of care. The new partnership with Regeneron aims to capitalize on this mechanistic profile; preclinical models suggest that the TopoIx payload in BHV-1530 may trigger immunogenic cell death, creating a synergistic effect when paired with immune checkpoint blockade. This collaboration deepens an existing relationship between the two firms, following a prior agreement focused on the TROP2-directed ADC, BHV-1510.